These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 24869597)

  • 21. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
    Christoforidou A; Kapsas G; Bezirgiannidou Z; Papamichos S; Kotsianidis Ι
    Turk J Haematol; 2018 May; 35(2):147-149. PubMed ID: 29391330
    [No Abstract]   [Full Text] [Related]  

  • 22. [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
    Wang M; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):245-9. PubMed ID: 24598688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
    Wanquet A; Birsen R; Lemal R; Hunault M; Leblond V; Aurran-Schleinitz T
    Blood; 2016 May; 127(19):2356-8. PubMed ID: 26994148
    [No Abstract]   [Full Text] [Related]  

  • 24. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
    Chan TS; Au-Yeung R; Chim CS; Wong SC; Kwong YL
    Ann Hematol; 2017 May; 96(5):871-872. PubMed ID: 28184982
    [No Abstract]   [Full Text] [Related]  

  • 27. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
    J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A mechanism-driven treatment for chronic lymphocytic leukemia?
    Foà R; Guarini A
    N Engl J Med; 2013 Jul; 369(1):85-7. PubMed ID: 23782159
    [No Abstract]   [Full Text] [Related]  

  • 29. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
    Burger JA; Buggy JJ
    Leuk Lymphoma; 2013 Nov; 54(11):2385-91. PubMed ID: 23425038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BTK
    Woyach JA; Ruppert AS; Guinn D; Lehman A; Blachly JS; Lozanski A; Heerema NA; Zhao W; Coleman J; Jones D; Abruzzo L; Gordon A; Mantel R; Smith LL; McWhorter S; Davis M; Doong TJ; Ny F; Lucas M; Chase W; Jones JA; Flynn JM; Maddocks K; Rogers K; Jaglowski S; Andritsos LA; Awan FT; Blum KA; Grever MR; Lozanski G; Johnson AJ; Byrd JC
    J Clin Oncol; 2017 May; 35(13):1437-1443. PubMed ID: 28418267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Kaur V; Swami A
    Ann Hematol; 2017 Jul; 96(7):1175-1184. PubMed ID: 28342031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new era of treatment for chronic lymphocytic leukaemia?
    Brown JR
    Lancet Oncol; 2014 Jan; 15(1):3-5. PubMed ID: 24332240
    [No Abstract]   [Full Text] [Related]  

  • 33. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
    Landau DA; Sun C; Rosebrock D; Herman SEM; Fein J; Sivina M; Underbayev C; Liu D; Hoellenriegel J; Ravichandran S; Farooqui MZH; Zhang W; Cibulskis C; Zviran A; Neuberg DS; Livitz D; Bozic I; Leshchiner I; Getz G; Burger JA; Wiestner A; Wu CJ
    Nat Commun; 2017 Dec; 8(1):2185. PubMed ID: 29259203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
    Jain N; O'Brien S
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):851-60, x. PubMed ID: 23915749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
    Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
    Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
    Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
    [No Abstract]   [Full Text] [Related]  

  • 37. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
    Lampson BL; Brown JR
    Expert Rev Hematol; 2018 Mar; 11(3):185-194. PubMed ID: 29381098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-generation inhibitors of Bruton tyrosine kinase.
    Wu J; Liu C; Tsui ST; Liu D
    J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
    Guinn D; Ruppert AS; Maddocks K; Jaglowski S; Gordon A; Lin TS; Larson R; Marcucci G; Hertlein E; Woyach J; Johnson AJ; Byrd JC
    Leukemia; 2015 May; 29(5):1210-3. PubMed ID: 25486872
    [No Abstract]   [Full Text] [Related]  

  • 40. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
    Cheng S; Guo A; Lu P; Ma J; Coleman M; Wang YL
    Leukemia; 2015 Apr; 29(4):895-900. PubMed ID: 25189416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.